Gosset Ownership
Private
Employees
~6
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Arrevus General Information
Arrevus has a Phase III clinical program (ARV-1801) targeting cystic fibrosis pulmonary exacerbations. Their lead DPC, ARV-1502, has successfully completed animal activity testing and has an issued US composition of matter patent[1][4].
Contact Information
Primary Industry
Biotech
Corporate Office
Durham, North Carolina
United States
United States
Drug Pipeline
sodium fusidate
Phase 2Key Partnerships
Arrevus Funding
No funding data available
To view Arrevus's complete valuation and funding history, request access »